title: CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target.
authors.forename: N
authors.initials: N
authors.lastname: Robillard
authors.forename: S
authors.initials: S
authors.lastname: Wuillème
authors.forename: L
authors.initials: L
authors.lastname: Lodé
authors.forename: F
authors.initials: F
authors.lastname: Magrangeas
authors.forename: S
authors.initials: S
authors.lastname: Minvielle
authors.forename: H
authors.initials: H
authors.lastname: Avet-Loiseau
mesh_terms: D000617:Aminoglycosides / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD / Q000032:analysis / Q000096:biosynthesis*; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis / Q000096:biosynthesis*; D014408:Biomarkers, Tumor / Q000032:analysis; D001854:Bone Marrow Cells; D000079982:Gemtuzumab; D020869:Gene Expression Profiling; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy / Q000276:immunology*; D010950:Plasma Cells; D011379:Prognosis; D063268:Sialic Acid Binding Ig-like Lectin 3
chemical_list: D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D014408:Biomarkers, Tumor; C571163:CD33 protein, human; D063268:Sialic Acid Binding Ig-like Lectin 3; D000079982:Gemtuzumab